Evidence map›Paper›PMID 37685953›Full record

ArticleInternational journal of molecular sciences2023

Differential Type-I Interferon Response in Buffy Coat Transcriptome of Individuals Infected with SARS-CoV-2 Gamma and Delta Variants.

Guilherme C da Fonseca, Liliane T F Cavalcante, Otávio J Brustolini, Paula M Luz, Debora C Pires, Emilia M Jalil, Eduardo M Peixoto, Beatriz Grinsztejn, Valdilea G Veloso, Sandro Nazer and 10 more

Abstract read
In one paragraph

Article in International journal of molecular sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Guilherme C da FonsecaLaboratório de Bioinformática, Laboratório Nacional de Computação Científica, Petrópolis, Rio de Janeiro 25651-076, Brazil.ORCID 0000-0002-0007-9834
Liliane T F CavalcanteLaboratório de Bioinformática, Laboratório Nacional de Computação Científica, Petrópolis, Rio de Janeiro 25651-076, Brazil.ORCID 0000-0002-4808-8158
Otávio J BrustoliniLaboratório de Bioinformática, Laboratório Nacional de Computação Científica, Petrópolis, Rio de Janeiro 25651-076, Brazil.
Paula M LuzInstituto Nacional de Infectologia Evandro Chagas, FIOCRUZ, Rio de Janeiro 21040-360, Brazil.
Debora C PiresInstituto Nacional de Infectologia Evandro Chagas, FIOCRUZ, Rio de Janeiro 21040-360, Brazil.
Emilia M JalilInstituto Nacional de Infectologia Evandro Chagas, FIOCRUZ, Rio de Janeiro 21040-360, Brazil.ORCID 0000-0001-6017-5660
Eduardo M PeixotoInstituto Nacional de Infectologia Evandro Chagas, FIOCRUZ, Rio de Janeiro 21040-360, Brazil.
Beatriz GrinsztejnInstituto Nacional de Infectologia Evandro Chagas, FIOCRUZ, Rio de Janeiro 21040-360, Brazil.
Valdilea G VelosoInstituto Nacional de Infectologia Evandro Chagas, FIOCRUZ, Rio de Janeiro 21040-360, Brazil.
Sandro NazerInstituto Nacional de Infectologia Evandro Chagas, FIOCRUZ, Rio de Janeiro 21040-360, Brazil.
Carlos A M CostaEscola Nacional de Saúde Pública, FIOCRUZ, Rio de Janeiro 21041-210, Brazil.
Daniel A M VillelaPrograma de Computação Científica (PROCC), FIOCRUZ, Rio de Janeiro 21040-900, Brazil.ORCID 0000-0001-8371-2959
Guilherme T GoedertEscola de Matemática Aplicada (EMAp), Fundação Getúlio Vargas, Rio de Janeiro 22250-900, Brazil.
Cleber V B D SantosInstituto de Medicina Social Hesio Cordeiro (IMS), Universidade do Estado do Rio de Janeiro, Rio de Janeiro 20550-013, Brazil.ORCID 0000-0001-5710-2866
Nadia C P RodriguesEscola Nacional de Saúde Pública, FIOCRUZ, Rio de Janeiro 21041-210, Brazil.ORCID 0000-0002-2613-5283
Fernando do Couto MottaInstituto Oswaldo Cruz, FIOCRUZ, Rio de Janeiro 21040-360, Brazil.
Marilda Mendonça SiqueiraInstituto Oswaldo Cruz, FIOCRUZ, Rio de Janeiro 21040-360, Brazil.
Lara E CoelhoInstituto Nacional de Infectologia Evandro Chagas, FIOCRUZ, Rio de Janeiro 21040-360, Brazil.
Claudio J StruchinerEscola de Matemática Aplicada (EMAp), Fundação Getúlio Vargas, Rio de Janeiro 22250-900, Brazil.ORCID 0000-0003-2114-847X
Ana Tereza R VasconcelosLaboratório de Bioinformática, Laboratório Nacional de Computação Científica, Petrópolis, Rio de Janeiro 25651-076, Brazil.ORCID 0000-0002-4632-2086

Funding

Fundação Carlos Chagas Filho de Amparo à Pesquisa do Estado do Rio de Janeiro E-26/210.179/202Fundação Carlos Chagas Filho de Amparo à Pesquisa do Estado do Rio de Janeiro E-26/211.107/2021
6 · The paper itself

Abstract

The innate immune system is the first line of defense against pathogens such as the acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The type I-interferon (IFN) response activation during the initial steps of infection is essential to prevent viral replication and tissue damage. SARS-CoV and SARS-CoV-2 can inhibit this activation, and individuals with a dysregulated IFN-I response are more likely to develop severe disease. Several mutations in different variants of SARS-CoV-2 have shown the potential to interfere with the immune system. Here, we evaluated the buffy coat transcriptome of individuals infected with Gamma or Delta variants of SARS-CoV-2. The Delta transcriptome presents more genes enriched in the innate immune response and Gamma in the adaptive immune response. Interactome and enriched promoter analysis showed that Delta could activate the INF-I response more effectively than Gamma. Two mutations in the N protein and one in the nsp6 protein found exclusively in Gamma have already been described as inhibitors of the interferon response pathway. This indicates that the Gamma variant evolved to evade the IFN-I response. Accordingly, in this work, we showed one of the mechanisms that variants of SARS-CoV-2 can use to avoid or interfere with the host Immune system.

Indexed as

COVID-19Interferon Type ISevere acute respiratory syndrome-related coronavirusHumansSARS-CoV-2TranscriptomeInterferon Type IDeltaGammainnate immune systemSARS-CoV-2 variantstype-I interferon responseviral evolution

Identifiers

PMID37685953
PMCPMC10487928

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.